Literature DB >> 15252311

Expression of RON Proto-oncogene in Renal Oncocytoma and Chromophobe Renal Cell Carcinoma.

Kurt T Patton1, Maria S Tretiakova, Jorge L Yao, Veronica Papavero, Lei Huo, Brian P Adley, Guan Wu, Jiaoti Huang, Michael R Pins, Bin T Teh, Ximing J Yang.   

Abstract

Recently, it was reported that RON proto-oncogene, encoding a receptor tyrosine kinase, was strongly expressed in renal oncocytomas but not in any renal cell carcinomas, including 5 chromophobe renal cell carcinomas, which morphologically resemble oncocytomas. To determine its diagnostic value, we studied Ron protein expression by immunohistochemistry in a larger number of renal cell neoplasms with emphasis on chromophobe renal cell carcinomas. Tissue microarrays containing 141 renal cell neoplasms, including 55 oncocytomas and 52 chromophobe renal cell carcinomas, were constructed. In addition, conventional sections from 15 cases of oncocytoma and 5 cases of chromophobe renal cell carcinoma were analyzed. Immunohistochemistry was carried out with a monoclonal mouse anti-human Ron-alpha antibody. Staining intensity was scored on a 0 to 3 scale. Ninety-nine percent of oncocytomas (69 of 70) and 96% of chromophobe renal cell carcinomas (55 of 57) showed moderate to strong, diffuse cytoplasmic Ron immunoreactivity with intensities > or =2, while only 17% of other renal cell carcinoma subtypes stained with intensities > or =2. Our study indicates that Ron immunostaining cannot be used to distinguish oncocytoma from chromophobe renal cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15252311     DOI: 10.1097/01.pas.0000128661.58697.7d

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  9 in total

Review 1.  Strategies of targeting the extracellular domain of RON tyrosine kinase receptor for cancer therapy and drug delivery.

Authors:  Omid Zarei; Silvia Benvenuti; Fulya Ustun-Alkan; Maryam Hamzeh-Mivehroud; Siavoush Dastmalchi
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-08       Impact factor: 4.553

2.  Prognostic significance of MST1R dysregulation in renal cell tumors.

Authors:  Ana S Pires-Luís; Márcia Vieira-Coimbra; Maria João Ferreira; João Ramalho-Carvalho; Pedro Costa-Pinheiro; Luís Antunes; Paula C Dias; Francisco Lobo; Jorge Oliveira; Inês Graça; Rui Henrique; Carmen Jerónimo
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

3.  Immunohistochemical application of S100A1 in renal oncocytoma, oncocytic papillary renal cell carcinoma, and two variants of chromophobe renal cell carcinoma.

Authors:  Naoto Kuroda; Naoki Kanomata; Tadanori Yamaguchi; Yoshiaki Imamura; Chisato Ohe; Noriko Sakaida; Ondrej Hes; Michal Michal; Taro Shuin; Gang-Hong Lee
Journal:  Med Mol Morphol       Date:  2011-06-30       Impact factor: 2.309

4.  Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors.

Authors:  Patricia M LoRusso; Mrinal Gounder; Shadia I Jalal; Valérie André; Siva Rama Prasad Kambhampati; Nick Loizos; Jennifer Hall; Timothy R Holzer; Aejaz Nasir; Jan Cosaert; John Kauh; E Gabriela Chiorean
Journal:  Invest New Drugs       Date:  2017-02-04       Impact factor: 3.850

Review 5.  Risk factors, classification, and staging of renal cell cancer.

Authors:  Damian A Laber
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

6.  Molecular classification of renal tumors by gene expression profiling.

Authors:  Audrey N Schuetz; Qiqin Yin-Goen; Mahul B Amin; Carlos S Moreno; Cynthia Cohen; Christopher D Hornsby; Wen Li Yang; John A Petros; Muta M Issa; John G Pattaras; Kenneth Ogan; Fray F Marshall; Andrew N Young
Journal:  J Mol Diagn       Date:  2005-05       Impact factor: 5.568

7.  BCA2 is differentially expressed in renal oncocytoma: an analysis of 158 renal neoplasms.

Authors:  Laleh Ehsani; Rishie Seth; Stephanie Bacopulos; Arun Seth; Adeboye O Osunkoya
Journal:  Tumour Biol       Date:  2012-12-15

Review 8.  Key clinical issues in renal cancer: a challenge for proteomics.

Authors:  Rosamonde E Banks; Rachel A Craven; Patricia Harnden; Sanjeev Madaan; Adrian Joyce; Peter J Selby
Journal:  World J Urol       Date:  2007-08-25       Impact factor: 4.226

9.  Diagnostic Utility of Caveolin-1 and MOC-31 in Distinguishing Chromophobe Renal Cell Carcinoma from Renal Oncocytoma.

Authors:  Hyoun Wook Lee; Eun Hee Lee; Chang Hun Lee; Hee Kyung Chang; Seo Hee Rha
Journal:  Korean J Urol       Date:  2011-02-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.